Georgina V. Long

1 week ago | thelancet.com | Georgina V. Long |Mater Hospitals |James Garrett |Victoria Atkinson

aRonald O Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York City, NY, USA bLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York City, NY, USA cMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia dRoyal North Shore and Mater Hospitals, Sydney, NSW, Australia eNovartis Pharmaceuticals Corporation, Cambridge, MA, USA fPrincess Alexandra Hospital, Gallipoli Medical Research Foundation, University of...

3 weeks ago | healio.com | Gabrielle Capaldo |Carol L. DiBerardino |Georgina V. Long

Key takeaways: The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%. Similarly, 48% of those patients achieved a 7-year overall survival. Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option.

Aug 14, 2024 | onclive.com | Georgina V. Long

CommentaryVideoAugust 14, 2024Author(s):Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial. Georgina V.

Aug 13, 2024 | brnw.ch | Georgina V. Long |Evan J. Lipson |F. Stephen Hodi

Authors' Disclosures of Potential Conflicts of InterestThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

Mar 1, 2024 | jitc.bmj.com | Dirk Schadendorf |Jason Luke |Paolo A Ascierto |Georgina V. Long

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.